Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145418 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Oncology Specialists, S.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00145418 is a Phase 2 study that was terminated before completion, run by Oncology Specialists, S.C.. The registered enrollment target is 15 participants.
The verdict
NCT00145418, a Phase 2 study, was terminated before completion, sponsored by Oncology Specialists, S.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
It has been accepted and proven that patients with unresectable lung cancer can benefit from systemic chemotherapy. Traditional platinum-based therapy has significant side effects. Oxaliplatin and docetaxel have both shown to be effective for lung cancer. The purpose of this study is to determine if oxaliplatin combined with docetaxel has a lower toxicity profile and to determine the response rate to this study drug combination.
Interventions
- DRUG Oxaliplatin + Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145418
The ClinicalTrials.gov registry entry for NCT00145418 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncology Specialists, S.C., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxaliplatin + Docetaxel is the first listed.
NCT00145418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00145418 about?
NCT00145418 is a clinical study titled "Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer". It has been accepted and proven that patients with unresectable lung cancer can benefit from systemic chemotherapy. Traditional platinum-based therapy has significant side effects. Oxaliplatin and docetaxel have both shown to be effective for lung cancer. The purpose of this study is to determine if...
What is the current status of trial NCT00145418?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2005-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00145418?
The interventions under investigation include: Oxaliplatin + Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00145418?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.